Q core’s Sapphire Infusion Pumps 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Hospira 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2016-05-24
  • 사례 출판 날짜
    2016-05-24
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
    ICU Medical, Inc. acquired from Pfizer in early 2017, Hospira Infusion Systems, the portion of Hospira dedicated to develop infusion pumps.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: hospira q core’s sapphire infusion pumps medical device manufacturer, hospira, has issued a medical device safety alert concerning q core’s sapphire infusion pumps (hospira list number: 163113601). the manufacturer’s investigation and analysis has determined that with specific drug concentrations of iron sucrose (range of 0.7 to 2.8mg/ml, “concentration range”) the pump may misinterpret the iron sucrose solution as air rather than an opaque solution, resulting in the generation of a false air-in-line alarm. risk to health is limited to a delay in the administration of iron sucrose infusion in the concentration range only. the issue, if occurs, is immediately apparent to the provider at the beginning of the treatment as an air-in-line alarm is generated, which does not allow the treatment to start. in addition, iron sucrose therapy is not used for acute treatment of anaemia, the effected of iron sucrose takes days to occur, and alternative delivery mechanism are readily available. thus the risks of delay in therapy of intravenous iron sucrose are remote. according to the manufacturer, intensive research has not revealed any other medication which raises the same issue, i.E., this issue is unique for iron sucrose and no other drug. the software algorithms within the pump are being improved to restore the device to its original specifications, enabling consistent delivery of the aforementioned concentration of iron sucrose. this improvement will address the root cause and prevent the false alarms. according to the local supplier, the affected products are distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 24 may 2016.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Hospira Q core’s Sapphire Infusion Pumps
  • Manufacturer

Manufacturer

  • 제조사 모회사 (2017)
  • Source
    DH